1. Home
  2. ELYM

ELYM

Eliem Therapeutics Inc

Logo Eliem Therapeutics Inc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).

Founded: 2018 Country:
United States
United States
Employees: N/A City: WILMINGTON
Market Cap: 74.6M IPO Year: 2021
Target Price: N/A AVG Volume (30 days): 693.2K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.30 EPS Growth: N/A
52 Week Low/High: $2.34 - $4.96 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: